Title:
CONSTITUTIVE CHIMERIC CYTOKINE RECEPTOR, IMMUNE CELL EXPRESSING SAME, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/051831
Kind Code:
A1
Abstract:
The present invention relates to a constitutive chimeric cytokine receptor, comprising an extracellular domain and a constitutively activated IL-7R mutant. The extracellular domain consists of an effector molecule capable of remodeling the tumor microenvironment, and the constitutively activated IL-7R mutant comprises an IL-7R mutant transmembrane domain and an IL-7R intracellular domain. The present invention also relates to a CAR polypeptide or a TCR polypeptide modified by the constitutive chimeric cytokine receptor, an immune effector cell engineered to express the CAR polypeptide or the TCR polypeptide modified by the constitutive chimeric cytokine receptor, and a method for preparing the immune effector cell. The immune effector cell expressing the CAR polypeptide or the TCR polypeptide modified by the constitutive chimeric cytokine receptor of the present invention can be used for treating a tumor in a subject.
Inventors:
WEI HUAFENG (CN)
YU ZHOU (CN)
HUANG DAN (CN)
TIAN JIYUAN (CN)
XU WEI (CN)
YU ZHOU (CN)
HUANG DAN (CN)
TIAN JIYUAN (CN)
XU WEI (CN)
Application Number:
PCT/CN2023/117778
Publication Date:
March 14, 2024
Filing Date:
September 08, 2023
Export Citation:
Assignee:
INNOVENT CELLS PHARMACEUTICALS SU ZHOU CO LTD (CN)
International Classes:
C07K19/00; A61K38/19; A61K38/20; A61K39/395; A61P35/00; C07K14/54; C07K14/715; C07K14/725; C12N15/24; C12N15/62
Foreign References:
| CN112368298A | 2021-02-12 | |||
| CN113383071A | 2021-09-10 | |||
| CN110892070A | 2020-03-17 | |||
| US20190292533A1 | 2019-09-26 | |||
| CN113543792A | 2021-10-22 |
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF:
Previous Patent: WASHING ASSEMBLY AND WASHING DEVICE
Next Patent: METHOD FOR DETECTING PROPORTION OF MRNA WITH POLYA TAIL IN MRNA PRODUCT
Next Patent: METHOD FOR DETECTING PROPORTION OF MRNA WITH POLYA TAIL IN MRNA PRODUCT